Bars and restaurants will close early and sporting events will be held without audiences under a three-week, partial lockdown that is expected to be announced in the Netherlands on Friday evening.
Europe has become the epicentre of the pandemic again, prompting some governments to consider re-imposing unpopular lockdowns in the run-up to Christmas and stirring debate over whether vaccines alone are enough to tame COVID-19.
Global COVID-19 cases surpassed 250 million on Monday as some countries in eastern Europe experience record outbreaks, even as the Delta variant surge eases and many countries resume trade and tourism.
Asia-Pacific countries, which have had some of the world’s strictest border controls and quarantine rules during the pandemic, are starting to open selectively to fully vaccinated international travellers as well as their unvaccinated children.
Following Facebook, US lawmakers are questioning internet companies like Snap,
U.S. President Joe Biden on Monday signed an order imposing new vaccine requirements for most foreign national air travelers and lifting severe travel restrictions on China, India and much of Europe effective Nov. 8, the White House said.
Doctors successfully performed an animal-to-human kidney transplant for the first
U.S. stock indexes edged higher on Wednesday, helped by strong quarterly updates from healthcare companies including Anthem and Abbott, while worries remained about the impact of supply chain constraints and inflation on corporate earnings.
The Australian state of New South Wales (NSW) confirmed the minimum daily increase in COVID 19 case scenarios in more than three weeks on Monday, following the relaxation of certain lockdown restrictions in Sydney, the state capital, allowing for higher vaccination levels. The Premier of New South Wales, Gladys Berejiklian,
akeda Pharmaceutical Co (4502.T), which distributes Moderna Inc’s (MRNA.O) COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory approval, its chief executive said.
Bars and restaurants will close early and sporting events will be held without audiences under a three-week, partial lockdown that is expected to be announced in the Netherlands on Friday evening.
Europe has become the epicentre of the pandemic again, prompting some governments to consider re-imposing unpopular lockdowns in the run-up to Christmas and stirring debate over whether vaccines alone are enough to tame COVID-19.
Global COVID-19 cases surpassed 250 million on Monday as some countries in eastern Europe experience record outbreaks, even as the Delta variant surge eases and many countries resume trade and tourism.
Asia-Pacific countries, which have had some of the world’s strictest border controls and quarantine rules during the pandemic, are starting to open selectively to fully vaccinated international travellers as well as their unvaccinated children.
Following Facebook, US lawmakers are questioning internet companies like Snap,
U.S. President Joe Biden on Monday signed an order imposing new vaccine requirements for most foreign national air travelers and lifting severe travel restrictions on China, India and much of Europe effective Nov. 8, the White House said.
Doctors successfully performed an animal-to-human kidney transplant for the first
U.S. stock indexes edged higher on Wednesday, helped by strong quarterly updates from healthcare companies including Anthem and Abbott, while worries remained about the impact of supply chain constraints and inflation on corporate earnings.
The Australian state of New South Wales (NSW) confirmed the minimum daily increase in COVID 19 case scenarios in more than three weeks on Monday, following the relaxation of certain lockdown restrictions in Sydney, the state capital, allowing for higher vaccination levels. The Premier of New South Wales, Gladys Berejiklian,
akeda Pharmaceutical Co (4502.T), which distributes Moderna Inc’s (MRNA.O) COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory approval, its chief executive said.
© | All rights reserved.
